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Novel Therapies for Resistant 
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A B S T R A C T
Two novel invasive therapeutic strategies for the treatment of resistant hypertension, 
have recently emerged, carotid baroreceptor stimulation and renal denervation. Both 
are effective in reducing elevated blood pressure values and display a good tolerability 
profile without the occurrence of any major untoward effect. A third choice, immuni-
zation against components of the renin-angiotensin-aldosterone system (RAAS) is a 
potential therapeutic alternative under investigation.
I N T R O D U C T I O N
Hypertension has a prevalence of 26.4% and affects nearly 72 million people in 
the USA, and 1 billion worldwide. Hypertension is a major cause of morbidity and 
mortality, responsible for 7 million deaths annually.1 It is estimated that only 25-35% 
of hypertensive patients achieve a blood pressure <140/90 mmHg. Hypertension is 
usually defined as resistant or refractory to treatment when a therapeutic plan that has 
included attention to lifestyle measures and the prescription of at least three drugs 
(including a diuretic) in a full daily dosage has failed to lower systolic and diastolic 
blood pressure <160/90 mmHg.
P R E V A L E N C E  A N D  H E A L T H  B U R D E N
Resistant hypertension has a reported prevalence as high as 13%. The high 
prevalence of hypertension in the general population renders this small percentage 
significant in terms of actual patient numbers. The most common causes of resistant 
hypertension is poor compliance or limitations in drug therapy (inadequate dosing, 
polypharmacy, and adverse drug effects) or non adherence to recommended lifestyle 
changes (particularly elimination of alcohol abuse). Another not infrequent cause 
of resistant hypertension is obstructive sleep apnea 736–739, whereas other causes 
include renal artery stenosis and volume overload -due to progressing renal insuffi-
ciency, excessive salt intake, hyperaldosteronism, and, most often, insufficient diuretic 
therapy. Finally pseudohypertension must be excluded.2,3 This creates the need for 
other therapeutic options, beyond existing antihypertensive medications, setting the 
basis for interventional approaches.
Recently, activation of the carotid baroreceptors using electrical stimuli (the 
Rheos System; CVRx, Inc., Minneapolis, Minnesota) is under investigation in phase 
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III studies, with promising results. Another study using selec-
tive renal sympathetic denervation (RSD) marks the return 
of selective renal sympathectomy as a potential alternative 
treatment for resistant hypertension. The sympathetic in-
nervation of the kidney is implicated in the pathogenesis of 
hypertension through effects on renin secretion, sodium and 
water reabsorption, and renal blood flow (RBF). Finally, 
immunization against components of the renin-angiotensin 
system (RAAS) have provided optimism in the development 
of another therapy for resistant hypertension.
C A R O T I D  S I N U S  S T I M U L A T I O N
The baroreflex is a series of responses to physiologic 
stimuli that determines the balance of sympathetic and para-
sympathetic activity in the heart and peripheral vessels and 
there be participates in long and short term control of blood 
pressure. Carotid baroreceptors physiologically modulate 
autonomic tone by inhibiting sympathetic cardiovascular drive 
and stimulating vagal infuences on the heart. This homeostatic 
function is impaired in hypertension leading to vasoconstric-
tion and tachycardia (Fig. 1). However, baroreceptor response 
diminishes over minutes to days, and a new threshold for 
activation is established (baroreceptors become less sensitive 
to any given change in blood pressure with chronic hyperten-
sion). Preliminary studies in experimental animals conducted 
to restore the baroreceptor function, showed that carotid 
sinus stimulation is able to lower blood pressure and reduce 
circulating levels of norepinephrine.4
D E V I C E  &  T E C H N I Q U E
The Rheos Baroreflex Hypertension Therapy System con-
sists of a programmable pulse generator capable of delivering 
between 1 and 7,5 V in a temporary variable pattern along 
with 2 electrodes designed to be placed at the carotid bulb. 
This requires surgical implantation by means of open carotid 
exposure, but the components are then tunneled subcutane-
ously, in a fashion similar to pacemaker placement (Fig. 2).11
O U T C O M E
The patients enrolled in the US and European Rheos 
Feasibility Trial, (all experiencing resistant hypertension while 
receiving optimal medical management) presented a systolic 
blood pressure (SPB) reduction of 41 mm Hg, (from 180 to 
139 mmHg), (P=0.001), diastolic blood pressure (DBP) of 
19 mm Hg, (P=0.005), pulse pressure from 98 to 77 mm Hg 
(=21 mm Hg), (P<0.005), and heart rate reduction of 9 bpm. 
In all cases, dose (voltage)-response curves were consistent, 
apparent and highly linear. 5,6 Mean follow up was 10 months. 
At the end of the study the stimulation procedure caused sus-
tained blood pressure reduction (31/14 mmHg) coupled with 
consistent sympatho-inhibition, without any major side effects. 
Two generators have had to be changed for planned battery 
replacement in patients requiring high voltages for blood pres-
sure control and the total infection rate was 5.5%.7-10
FIGURE 2. Position of the Carotid Sinus Leads and Impulse 
generator.FIGURE 1. Aortic and Carotid Receptors.
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R E N A L  S Y M P A T H E T I C  D E N E R V A T I O N 
( R S D )
The autonomic control of the kidney is predominantly 
sympathetic with postganglionic neurons. Renal sympathetic 
nerve activation enhances noradrenaline production or sp-
illover (while renal denervation results in a marked decrease 
of noradrenaline up to 95%), renin secretion via b
1
AR when 
the nerve stimulation is weak, and sodium reabsorption and 
renal vessel vasoconstriction via a
1
AR, resulting in renal blood 
flow reduction (vascular smooth muscle cell contraction, more 
profound in preglomerular microvessels), when sympathetic 
nerve stimulation is stronger.
Efferent renal sympathetic nerve endings release noradren-
aline directly on granular juxtaglomerular cells and increase 
the rate of renin release as well as indirectly by interfering 
with renal hemodynamics and sodium reabsorption (release of 
noradrenaline directly on renal epithelial cells and promotion 
of reabsorption of water and sodium from the tubular lumen 
in the proximal tubule and thick ascending limb of Henle’s 
loop). Moreover, afferent renal sympathetic nerves originate 
mostly from the renal pelvic wall (mechanoreceptors respond 
to stretch and chemoreceptors detect renal ischemia) whose 
cell bodies lie in the ipsilateral dorsal root ganglia (T6-L4). 
From there ascending signals travel mainly in hypothalamic 
area stimulating sympathetic centers in the brain thus increas-
ing sympathetic nervous system (SNS) activity and blood 
pressure levels.
H I S T O R I C A L  P E R S P E C T I V E  O F  S Y M PA T H E T I C 
D E N E R VA T I O N
Sympathectomy has been applied manly in patients with 
severe or malignant hypertension as well as with patients of 
cardiovascular deterioration despite relatively good blood 
pressure reduction by other means. After the introduction 
of antihypertensive drugs, sympathectomy was reserved for 
patients who failed to respond to antihypertensive therapy 
or could not tolerate it. Total sympathectomy (from 8th to 
12th dorsal vertebra) is impractical and poorly tolerated by 
humans. It was performed only in a few selected centers, in 
either 1 or 2 stages, and required a prolonged hospital stay 
(2 to 4 weeks). Adverse events were common and included 
orthostatic hypotension and tachycardia, palpitation, breath-
lessness, anhydrosis, cold hands, intestinal disturbances, loss 
of ejaculation, sexual dissatisfaction, thoracic duct injuries 
and atelectasies. However, sympathectomy was associated 
with higher survival rates more than doubled in patients who 
underwent the procedure.
T E C H N I Q U E
Renal artery angiography is performed to access anatomic 
eligibility for the procedure and to confirm the absence of 
significant renal artery stenosis. The treatment catheter is 
then introduced into the renal artery and positioned in the 
distal part of the artery. The proximal end of the catheter 
is connected to a radiofrequency (RF) generator to apply a 
discrete RF ablation lasting 2 min. Up to six ablations are 
performed in each artery, separated both longitudinally and 
rotationally to achieve circumferential coverage of the renal 
artery. Catheter tip temperature and impedance are constantly 
monitored during ablation and RF energy delivery is regulated 
according to a predetermined algorithm (Fig. 3).12
C U R R E N T  U S E  O F  R S D
RSD presents several significant advantages over radical 
sympathectomy:
Ιt is localized, minimal invasive, it has no systemic side ef-
fects and its procedural and recovery time are very short. It was 
achieved by radiofrequency ablation trough the percutaneous 
insertion of modified catheter (Symplicity; Ardian Inc., Palo 
Alto, California). It was studied in 50 patients with resistant 
hypertension and resulted in impressive blood pressure reduc-
tions (27/11 mmHg) during a 12-month follow up period. Only 
2 adverse events occurred (one renal artery dissection and one 
femoral artery pseudoaneurysm).13 This study demonstrated 
for the first time in humans that RSD can reduce blood 
pressure in a safe way with long acting results. However, the 
study lacked a proper control group (not randomized), it was 
FIGURE 3. Anatomy of the kidney.
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small, the group of patients recruited was not clearly defined, 
predictors of blood pressure response had not been identified, 
the potential for tissue damage (that will result in structural 
changes of the renal artery) was not defined. The extent of 
ablation induced afferent RSD is not currently known and the 
cost effectiveness needs to be carefully examined.14,15
T H E  F U T U R E  O F  R S D
RSD will be applied in other conditions such as essential 
hypertension, left ventricular hypertrophy (LVH), congestive 
heart failure (CHF), chronic kidney disease (CKD). Although 
attractive, RSD at the early stages of hypertension as well as 
in milder forms of the disease is difficult to accept at present 
time. Current recommendations suggest that it should be re-
served for patients in whom drug therapy fails. However, in the 
future maybe RSD can be used as initial therapy in younger 
patients obtaining most of the benefit. Similar beneficial ef-
fects in heart failure has been obtained in animal experiments 
with the Rheos System inducing carotic baroreceptor activa-
tion and subsequently inhibiting SNS activity.
I M M U N I Z A T I O N  A G A I N S T  C O M P O N E N T S 
O F  T H E  R E N I N - A N G I O T E N S I N 
A L D O S T E R O N E  S Y S T E M  ( R A A S )
The RAAS commands an important role in the regula-
tion of blood pressure and thus, at present, has been a target 
for clinical control by drugs affecting the entire system. Most 
recently, immunization against angiotensin-I with PMD-3117 
vaccine, angiotensin II with CYT006-AngQb vaccine and tar-
geting angiotensin-II type 1A receptor with ATR12181 vaccine 
have provided optimism in the development of a hypertension 
vaccine (Fig. 4).
R E N I N  I M M U N I Z A T I O N
Active immunization against the protein renin produced 
a high titre of renin antibodies, complete inhibition of endog-
enous plasma renin activity and decrease in blood pressure, but 
with presence of an auto-immune disease specific to the kidney 
-characterized by immunoglobulines colocalized with renin 
in the afferent arterioles, cellular inflammatory proliferation 
around the intrarenal arterial tree and interstitial nephritis.
A N G I O T E N S I N - I I  I M M U N I Z A T I O N
Immunization against angiotensin peptides requires the 
covalent linkage of the peptide to a protein carrier molecule a 
process with increases the level of immunological background 
by raising antibodies against the carrier. Also, synthetic 
angiotensin-II was coupled to Bovine serum albumin and 
emulsified in Freund’s adjuvant developing antibody titre 
6-15 times greater, but did not alter blood pressure. A new 
immunization technology that conjugates antigens to the 
surface of virus like particles (VLPs) leads to strong B-cell 
response against self antigens was utilized. VLP conjugates 
with either a peptide or a hapten have been tested in clinical 
trials, and have been shown to be well tolerated and highly 
immunogenic with a 100% responder rate. This vaccine terms 
CYT006-AngQb, increase reversibly antibodies, producing a 
difference of 21 mm Hg of blood pressure and lasting more 
than 35 days after the last boost (half life of 4 months).16 In 
a trial (Ambuhl et al.18) using this vaccine 14 of 16 subjects 
showed local adverse events such erythema, edema, pain and 
induration at the injection site, all of mild intensity. Another 
study (Tissot et al.19) phase IIa trial using 72 patients receiving 
100 μg or 300 μg AngQb responded with high IgG titres against 
AngII after only one injection and the antibody response was 
strongly boosted after the 2nd injection. In the 300 μg group 
the difference from placebo was in mean ambulatory blood 
pressure at 14th week was -9/-4 mm Hg. There was a significant 
reduction of the early-morning blood pressure surge compared 
with placebo in the 300 μg group, with a chance at 08:00am 
of -25/-13 mm Hg. Change from supine to standing position 
did not lead to orthostatic hypotention. This trial is the first 
to show that vaccination against vasoactive endogenous sub-
stance can reduce blood pressure in humans. The drop in 
blood pressure was pronounced in the early morning, when 
the R A S is most active and most stroke and cardiovascular 
events occur.
However, concerns of safety issue remain as 1) repeated 
stimulation of the immune system by booster doses of endog-
enous peptide linked to a virus like particle can cause auto-
immune disease. 2) whether continuous inhibition of AngII 
FIGURE 4. Vaccines against components of RAAS.
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for several months without the ability to quickly reverse it, is 
safe or does this inhibition play any detrimental role in situa-
tions of volume depletion, trauma, or shock. 3) because most 
of AngII is synthesized locally in tissues whether this antibody 
can diffuse from the circulation into the extravascular space 
in concentrations enough to block the local AngII. 4) or if it 
has organ protective effect.
A N G I O T E N S I N - I  I M M U N I Z A T I O N
AngI vaccine PMD3117 produced an anti-(AngI) antibody 
titre elevation, without influence in the BP, but with signifi-
cantly blunted fall of plasma renin following withdrawal of 
ACEi or ARB.17
A N G I O T E N S I N E  I I -T Y P E  1 A  ( A T 1 A )  R E C E P T O R 
I M M U N I Z A T I O N
Virus-like particle VLP based antihypertensive vaccine 
ATR 12181 which utilizes a peptide from the extracellular 
portion of AT1A receptor has been used in the reduction of 
anti –ATR 12181 antibodies. 17 mm Hg reduction of SBP was 
observed in slow heart rates at the 64th week with significant 
attenuation of LVH and reduction of LV fibrosis. Damages of 
glomerulus and interstitial fibrosis in kidneys were attenuated 
in vaccinated group and microscopic examination of different 
organs did not reveal any signs of auto immune disease and 
expression of the nuclear oncogenes c-fos and c-jun in heart 
and kidney were decreased in comparison to the control 
group. The long-term results of vaccine ATR 12181 in SHRs 
seemed to be encouraged in blood pressure lowering, target 
organ remodeling, efficacy and safety and thus, appropriate 
for future clinical utility.
In conclusion, if vaccination against high blood pressure 
proves to be safe and effective in the long run, it will increase 
the control rate of hypertension and thus, ease the burden of 
cardiovascular morbidity and mortality in our society.
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